NL301065I2 - Ozanimod of een farmaceutisch aanvaardbaar zout daarvan, in het bijzonder ozanimodhydrochloride - Google Patents

Ozanimod of een farmaceutisch aanvaardbaar zout daarvan, in het bijzonder ozanimodhydrochloride Download PDF

Info

Publication number: NL301065I2
Authority: NL; Netherlands
Prior art keywords: ozanimod; pharmaceutically acceptable; acceptable salt; hydrochloride; ozanimod hydrochloride
Prior art date: 2008-05-14

Application number

NL301065C

Other languages

English (en)

Other versions

NL301065I1 (nl

Original Assignee

Scripps Research Inst

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2008-05-14

Filing date

2020-09-30

Publication date

2020-10-28

2020-09-30 Application filed by Scripps Research Inst filed Critical Scripps Research Inst

2020-09-30 Publication of NL301065I1 publication Critical patent/NL301065I1/nl

2020-10-28 Publication of NL301065I2 publication Critical patent/NL301065I2/nl

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4245—Oxadiazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
- C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
- C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Immunology (AREA)
Epidemiology (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Transplantation (AREA)
Neurosurgery (AREA)
Pulmonology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Plural Heterocyclic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

NL301065C 2008-05-14 2020-09-30 Ozanimod of een farmaceutisch aanvaardbaar zout daarvan, in het bijzonder ozanimodhydrochloride NL301065I2 (nl)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US12760308P	2008-05-14	2008-05-14
PCT/US2009/003014 WO2009151529A1 (en)	2008-05-14	2009-05-14	Novel modulators of sphingosine phosphate receptors
US12/465,767 US8796318B2 (en)	2008-05-14	2009-05-14	Modulators of sphingosine phosphate receptors

Publications (2)

Publication Number	Publication Date
NL301065I1 NL301065I1 (nl)	2020-09-30
NL301065I2 true NL301065I2 (nl)	2020-10-28

Family

ID=41416994

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NL301065C NL301065I2 (nl)	2008-05-14	2020-09-30	Ozanimod of een farmaceutisch aanvaardbaar zout daarvan, in het bijzonder ozanimodhydrochloride

Country Status (20)

Country	Link
US (8)	US8796318B2 (nl)
EP (3)	EP2913326B1 (nl)
JP (2)	JP5837417B2 (nl)
AU (2)	AU2009258242B2 (nl)
CY (2)	CY1123338T1 (nl)
DK (1)	DK2291080T3 (nl)
EA (1)	EA021672B1 (nl)
ES (2)	ES2549761T3 (nl)
FI (2)	FI2291080T5 (nl)
HR (1)	HRP20150982T1 (nl)
HU (2)	HUE025984T2 (nl)
LT (1)	LTC2291080I2 (nl)
MY (2)	MY172105A (nl)
NL (1)	NL301065I2 (nl)
NO (1)	NO2020034I1 (nl)
NZ (1)	NZ589617A (nl)
PL (2)	PL2913326T3 (nl)
PT (2)	PT2913326T (nl)
SI (1)	SI2291080T1 (nl)
WO (1)	WO2009151529A1 (nl)

Families Citing this family (71)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
RU2447071C2 (ru)	2006-09-07	2012-04-10	Актелион Фармасьютиклз Лтд	Производные пиридин-4-ила в качестве иммуномодулирующих агентов
ES2450750T3 (es)	2007-03-16	2014-03-25	Actelion Pharmaceuticals Ltd.	Derivados de amino-piridina como agonistas del receptor S1P1/EDG1
CA2695509A1 (en)	2007-08-17	2009-02-26	Actelion Pharmaceuticals Ltd	Pyridine derivatives as s1p1/edg1 receptor modulators
KR20100092473A (ko)	2007-11-01	2010-08-20	액테리온 파마슈티칼 리미티드	신규한 피리미딘 유도체
US8148410B2 (en)	2007-12-10	2012-04-03	Actelion Pharmaceuticals Ltd.	Thiophene derivatives as agonists of S1P1/EDG1
KR20100125380A (ko)	2008-03-07	2010-11-30	액테리온 파마슈티칼 리미티드	신규한 아미노메틸 벤젠 유도체
WO2009151529A1 (en)	2008-05-14	2009-12-17	The Scripps Research Institute	Novel modulators of sphingosine phosphate receptors
AU2009266098B2 (en)	2008-06-09	2015-01-22	Ludwig-Maximilians-Universitat Munchen	New drug for inhibiting aggregation of proteins involved in diseases linked to protein aggregation and/or neurodegenerative diseases
US8217028B2 (en) *	2008-06-20	2012-07-10	Glaxo Group Limited	1,2,4-oxadiazole indole compounds
SI2326621T1 (sl)	2008-07-23	2016-10-28	Arena Pharmaceuticals, Inc.	Substituirani derivati 1,2,3,4-tetrahidrociklopenta(b)indol-3-il)ocetne kisline, uporabni pri zdravljenju avtoimunskih in vnetnih motenj
KR101800595B1 (ko)	2008-08-27	2017-11-22	아레나 파마슈티칼스, 인크.	자가면역 및 염증성 장애의 치료에 유용한, ｓ1ｐ1 수용체 효능제로서의 치환된 트리시클릭 산 유도체
JP2012515789A (ja)	2009-01-23	2012-07-12	ブリストル−マイヤーズスクイブカンパニー	スフィンゴシン−１−リン酸アゴニストとしてのピラゾール−１，２，４−オキサジアゾール誘導体
US8354398B2 (en)	2009-01-23	2013-01-15	Bristol-Myers Squibb Company	Substituted isoxazole compounds
EP2389377B1 (en)	2009-01-23	2014-07-16	Bristol-Myers Squibb Company	Substituted oxadiazole derivatives as s1p agonists in the treatment of autoimmune and inflammatory diseases
PT2454255E (pt)	2009-07-16	2014-01-14	Actelion Pharmaceuticals Ltd	Derivados de piridin-4-il como agonistas de s1/p1/edg1
US8399451B2 (en)	2009-08-07	2013-03-19	Bristol-Myers Squibb Company	Heterocyclic compounds
EA025672B1 (ru) *	2009-11-13	2017-01-30	Рецептос Ллк	Селективные гетероциклические модуляторы рецептора сфингозин-1-фосфата
MY160907A (en) *	2009-11-13	2017-03-31	Receptos Inc	Sphingosine 1 phosphate receptor modulators and methods of chiral synthesis
PH12012500939A1 (en) *	2009-11-13	2016-06-15	Receptos Llc	Selective sphingosine 1 phosphate receptor modulators and methods of chiral synthesis
AU2015202660B2 (en) *	2009-11-13	2016-10-27	Receptos Llc	Selective sphingosine 1 phosphate receptor modulators and methods of chiral synthesis
CN103221391B (zh)	2010-01-27	2018-07-06	艾尼纳制药公司	(R)-2-(7-(4-环戊基-3-(三氟甲基)苄基氧基)-1,2,3,4-四氢环戊二烯并[b]吲哚-3-基)乙酸及其盐的制备方法
WO2011109471A1 (en)	2010-03-03	2011-09-09	Arena Pharmaceuticals, Inc.	Processes for the preparation of s1p1 receptor modulators and crystalline forms thereof
EP2390252A1 (en) *	2010-05-19	2011-11-30	Almirall, S.A.	New pyrazole derivatives
EP2619190B1 (en) *	2010-09-24	2015-08-12	Bristol-Myers Squibb Company	Substituted oxadiazole compounds and their use as s1p1 agonists
KR101869120B1 (ko)	2011-01-19	2018-06-19	이도르시아 파마슈티컬스 리미티드	2-메톡시-피리딘-4-일 유도체
WO2012118935A1 (en)	2011-03-03	2012-09-07	Proteotech Inc	Compounds for the treatment of neurodegenerative diseases
CN102718726A (zh) *	2011-03-31	2012-10-10	上海铂力生物科技有限公司	作为免疫调节剂的(z)-5-苯亚甲基噻唑啉-4-酮衍生物
EP2706999B1 (en) *	2011-05-13	2019-08-28	Celgene International II Sàrl	Selective heterocyclic sphingosine 1 phosphate receptor modulators
EP2567959B1 (en)	2011-09-12	2014-04-16	Sanofi	6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
US9199975B2 (en)	2011-09-30	2015-12-01	Asana Biosciences, Llc	Biaryl imidazole derivatives for regulating CYP17
US9505728B2 (en)	2012-03-09	2016-11-29	Inception 2, Inc.	Triazolone compounds and uses thereof
CN104918922B (zh)	2012-12-20	2017-04-26	因森普深2公司	三唑酮化合物及其用途
US9540362B2 (en)	2013-02-20	2017-01-10	Lg Life Sciences Ltd.	Sphingosine-1-phosphate receptor agonists, methods of preparing the same, and pharmaceutical compositions containing the same as an active agent
CA2900910C (en) *	2013-03-15	2021-03-30	Actelion Pharmaceuticals Ltd	Pyridin-4-yl derivatives
WO2015035059A1 (en)	2013-09-06	2015-03-12	Inception 2, Inc.	Triazolone compounds and uses thereof
EP2853532B1 (en) *	2013-09-28	2020-12-09	Instytut Farmakologii Polskiej Akademii Nauk	1,2,4-oxadiazole derivatives as allosteric modulators of metabotropic glutamate receptors belonging to group III
US20170165236A1 (en) *	2013-11-01	2017-06-15	Celgene International Ii Sàrl	Selective sphingosine 1 phosphate receptor modulators and combination therapy therewith
CA2990028A1 (en) *	2014-06-26	2015-12-30	Monash University	Enzyme interacting agents
NZ734220A (en)	2015-01-06	2022-01-28	Arena Pharm Inc	Methods of treating conditions related to the s1p1 receptor
WO2016164180A1 (en)	2015-04-06	2016-10-13	Auspex Pharmaceuticals, Inc.	Deuterium-substituted oxadiazoles
TWI711609B (zh)	2015-05-20	2020-12-01	瑞士商愛杜西亞製藥有限公司	結晶形式
MA42807A (fr)	2015-06-22	2018-07-25	Arena Pharm Inc	Sel l-arginine cristallin d'acide (r)-2-(7-(4-cyclopentyl-3-(trifluorométhyl)benzyloxy)-1,2,3,4-tétrahydrocyclo-penta[b]indol-3-yl)acétique (composé 1) pour une utilisation dans des troubles associés au récepteur de s1p1
CN109219597A (zh)	2016-06-14	2019-01-15	苏州科睿思制药有限公司	奥扎莫德的晶型、其盐酸盐的晶型及其制备方法
CN109563059A (zh)	2016-08-19	2019-04-02	苏州科睿思制药有限公司	奥扎莫德的晶型及其制备方法
WO2018050091A1 (zh)	2016-09-14	2018-03-22	苏州科睿思制药有限公司	奥扎莫德盐酸盐的晶型及其制备方法
CA3038106A1 (en)	2016-09-29	2018-04-05	Celgene International Ii Sarl	Compounds and methods for treating lupus
EP3570740B1 (en)	2017-01-23	2023-08-30	Naqi Logix Inc.	Apparatus and method for using imagined direction to perform at least one action
CA3053418A1 (en)	2017-02-16	2018-08-23	Arena Pharmaceuticals, Inc.	Compounds and methods for treatment of primary biliary cholangitis
KR20190113955A (ko)	2017-02-16	2019-10-08	아레나 파마슈티칼스, 인크.	장-외 증상을 갖는 염증성 장질환의 치료를 위한 화합물 및 방법
US10981900B2 (en) *	2017-02-28	2021-04-20	Medshine Discovery Inc.	Spiro compound and use thereof
US20210163485A1 (en) *	2017-05-17	2021-06-03	Oppilan Pharma Ltd.	Heterocyclic Compounds for the Treatment of Disease
CN110944982A (zh)	2017-08-31	2020-03-31	苏州科睿思制药有限公司	奥扎莫德盐酸盐的晶型及其制备方法
WO2019094409A1 (en)	2017-11-07	2019-05-16	Teva Pharmaceuticals International Gmbh	Salts and solid state forms of ozanimod
AU2019280822A1 (en)	2018-06-06	2021-01-07	Arena Pharmaceuticals, Inc.	Methods of treating conditions related to the S1P1 receptor
KR20210074291A (ko)	2018-09-06	2021-06-21	아레나 파마슈티칼스, 인크.	자가면역 및 염증성 장애의 치료에 유용한 화합물
AR116479A1 (es)	2018-09-25	2021-05-12	Quim Sintetica S A	Intermediarios para la síntesis de ozanimod y procedimiento para la preparación del mencionado agonista del receptor de esfingosina-1-fosfato y de dichos intermediarios
WO2020152718A1 (en)	2019-01-25	2020-07-30	Mylan Laboratories Limited	Polymorphic forms 5-[3-[(1s)-2,3-dihydro-1-[(2-hydroxyethyl) amino]-1h-inden-4-yl]-1,2,4-oxadiazol-5-yl]-2-(1-methylethoxy)benzonitrile
US20220227722A1 (en) *	2019-04-26	2022-07-21	Receptos Llc	Sphingosine 1 phosphate receptor modulator
CN112062785B (zh) *	2019-06-11	2023-06-27	广东东阳光药业有限公司	奥扎莫德及其中间体的制备方法
WO2021026479A1 (en) *	2019-08-07	2021-02-11	Stamford, Andrew	Small molecule inhibitors of s1p2 receptor and uses thereof
AU2020407664A1 (en)	2019-12-20	2022-08-18	Tenaya Therapeutics, Inc.	Fluoroalkyl-oxadiazoles and uses thereof
EP4126829A1 (en) *	2020-03-27	2023-02-08	Receptos Llc	Sphingosine 1 phosphate receptor modulators
JP2023518968A (ja) *	2020-03-27	2023-05-09	レセプトス・リミテッド・ライアビリティ・カンパニー	スフィンゴシン１ホスフェート受容体モジュレーター
KR20220158743A (ko) *	2020-03-27	2022-12-01	리셉토스 엘엘씨	스핑고신 1 포스페이트 수용체 조절제
WO2021207051A1 (en) *	2020-04-06	2021-10-14	Bristol-Myers Squibb Company	Methods of treating acute respiratory disorders
US20230233532A1 (en) *	2020-06-26	2023-07-27	The Penn State Research Foundation	Sphingosine-1-phosphate receptor 1 agonist and liposomal formulations thereof
CA3191164A1 (en) *	2020-08-10	2022-02-17	Dana-Farber Cancer Institute, Inc.	Substituted 1,2,4-oxadiazoles as small molecule inhibitors of ubiquitin-specific protease 28
TW202308619A (zh)	2021-05-04	2023-03-01	美商特納亞治療股份有限公司	用於治療代謝疾病和hfpef的hdac6抑制劑
WO2023152767A1 (en)	2022-02-11	2023-08-17	Mylan Laboratories Limited	Polymorphic forms of ozanimod hydrochloride
WO2024246174A1 (en)	2023-05-31	2024-12-05	Química Sintética, S.A.	Amorphous and crystalline form of ozanimod hydrochloride
US11905265B1 (en) *	2023-10-13	2024-02-20	King Faisal University	3,4-dimethoxy-n′-(2-(5-phenyl-1,3,4-oxadiazol-2ylthio)acetoxy)benzimidamide as an antimicrobial compound

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3647809A (en) *	1968-04-26	1972-03-07	Chinoin Gyogyszer Es Vegyeszet	Certain pyridyl-1 2 4-oxadiazole derivatives
ID25477A (id)	1998-01-23	2000-10-05	Sankyo Co	Turunan-turunan spiropiperidin
DE10240818A1 (de)	2002-08-30	2004-05-13	Grünenthal GmbH	Substituierte 2-Pyrrolidin-2-yl-[1,3,4]-oxadiazol-Derivate
EP1581509B1 (en)	2002-12-20	2011-01-19	Merck Sharp & Dohme Corp.	1-(amino)indanes as edg receptor agonists
JP2006524638A (ja)	2003-04-30	2006-11-02	メルクフロストカナダリミテツド	８−（３−ビアリール）フェニルキノリン系ホスホジエステラーゼ−４阻害薬
US20050075375A1 (en) *	2003-05-14	2005-04-07	Anadys Pharmaceuticals, Inc.	Heterocyclic compounds for treating hepatitis C virus
WO2005032465A2 (en)	2003-10-01	2005-04-14	Merck & Co., Inc.	3,5-aryl, heteroaryl or cycloalkyl substituted-1,2,4-oxadiazoles as s1p receptor agonists
US7605171B2 (en)	2003-12-17	2009-10-20	Merck & Co., Inc.	(3,4-disubstituted)propanoic carboxylates as S1P (Edg) receptor agonists
WO2005058845A2 (en) *	2003-12-19	2005-06-30	Novo Nordisk A/S	Novel glucagon antagonists/inverse agonists
US7585881B2 (en)	2004-02-18	2009-09-08	Astrazeneca Ab	Additional heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists
PT1650186E (pt) *	2004-10-22	2008-09-16	Bioprojet Soc Civ	Novos derivados de ácidos dicarboxílicos
EP1851188A1 (en)	2005-02-22	2007-11-07	Teva Pharmaceutical Industries Limited	Improved process for the synthesis of enantiomeric indanylamine derivatives
CA2610310A1 (en)	2005-06-08	2006-12-14	Novartis Ag	Polycyclic oxadiazoles or isoxazoles and their use as s1p receptor ligands
WO2007003604A2 (en)	2005-07-04	2007-01-11	Novo Nordisk A/S	Hists1mine h3 receptor antagonists
CN101346372B (zh)	2005-12-23	2011-09-28	弗·哈夫曼-拉罗切有限公司	芳基-异唑-4-基-二唑衍生物
AU2007236707C1 (en)	2006-04-03	2012-05-24	Astellas Pharma Inc.	Hetero compound
US20080015193A1 (en)	2006-06-20	2008-01-17	Mendoza Jose S	Certain azoles exhibiting ATP-utilizing enzyme inhibitory activity, compositions, and uses thereof
US20080009534A1 (en)	2006-07-07	2008-01-10	Bristol-Myers Squibb Company	Substituted acid derivatives useful as antidiabetic and antiobesity agents and method
MX2009003129A (es)	2006-09-29	2009-04-06	Novartis Ag	Derivados de oxadiazol con propiedades anti-inflamatorias e inmunosupresoras.
CA2669104A1 (en) *	2006-11-21	2008-05-29	University Of Virginia Patent Foundation	Hydrindane analogs having sphingosine 1-phosphate receptor agonist activity
JP2010513283A (ja)	2006-12-15	2010-04-30	アボット・ラボラトリーズ	新規なオキサジアゾール化合物
JO2701B1 (en)	2006-12-21	2013-03-03	جلاكسو جروب ليميتد	Vehicles
US20090188269A1 (en)	2008-01-25	2009-07-30	Henkel Corporation	High pressure connection systems and methods for their manufacture
KR101582910B1 (ko)	2008-05-14	2016-01-08	더 스크립스 리서치 인스티튜트	스핑고신 포스페이트 수용체의 신규한 모듈레이터
WO2009151529A1 (en)	2008-05-14	2009-12-17	The Scripps Research Institute	Novel modulators of sphingosine phosphate receptors

2009
- 2009-05-14 WO PCT/US2009/003014 patent/WO2009151529A1/en active Application Filing
- 2009-05-14 EP EP15158887.8A patent/EP2913326B1/en active Active
- 2009-05-14 SI SI200931271T patent/SI2291080T1/sl unknown
- 2009-05-14 FI FIEP09762826.7T patent/FI2291080T5/fi active
- 2009-05-14 AU AU2009258242A patent/AU2009258242B2/en active Active
- 2009-05-14 ES ES09762826.7T patent/ES2549761T3/es active Active
- 2009-05-14 MY MYPI2015000801A patent/MY172105A/en unknown
- 2009-05-14 EP EP20185750.5A patent/EP3782991A1/en not_active Withdrawn
- 2009-05-14 PL PL15158887T patent/PL2913326T3/pl unknown
- 2009-05-14 ES ES15158887T patent/ES2813368T3/es active Active
- 2009-05-14 HU HUE09762826A patent/HUE025984T2/hu unknown
- 2009-05-14 MY MYPI2010005338A patent/MY156381A/en unknown
- 2009-05-14 US US12/465,767 patent/US8796318B2/en active Active
- 2009-05-14 EP EP09762826.7A patent/EP2291080B1/en active Active
- 2009-05-14 PT PT151588878T patent/PT2913326T/pt unknown
- 2009-05-14 PT PT97628267T patent/PT2291080E/pt unknown
- 2009-05-14 NZ NZ589617A patent/NZ589617A/en unknown
- 2009-05-14 JP JP2011509488A patent/JP5837417B2/ja active Active
- 2009-05-14 PL PL09762826T patent/PL2291080T3/pl unknown
- 2009-05-14 DK DK09762826.7T patent/DK2291080T3/en active
- 2009-05-14 EA EA201001785A patent/EA021672B1/ru unknown
2012
- 2012-09-06 US US13/605,427 patent/US8466183B2/en active Active
- 2012-09-06 US US13/605,358 patent/US8530503B2/en active Active
- 2012-09-06 US US13/605,561 patent/US8481573B2/en active Active
2014
- 2014-06-23 US US14/311,825 patent/US9382217B2/en active Active
2015
- 2015-08-12 AU AU2015213309A patent/AU2015213309B2/en active Active
- 2015-09-17 HR HRP20150982TT patent/HRP20150982T1/hr unknown
- 2015-11-05 JP JP2015217236A patent/JP2016041736A/ja active Pending
2016
- 2016-06-21 US US15/188,132 patent/US20170050941A1/en not_active Abandoned
2017
- 2017-09-22 US US15/713,237 patent/US9975863B2/en active Active
2018
- 2018-04-23 US US15/959,935 patent/US10544136B2/en active Active
2020
- 2020-09-11 CY CY20201100862T patent/CY1123338T1/el unknown
- 2020-09-24 FI FIC20200037C patent/FIC20200037I1/fi unknown
- 2020-09-29 NO NO2020034C patent/NO2020034I1/no unknown
- 2020-09-30 NL NL301065C patent/NL301065I2/nl unknown
- 2020-10-01 LT LTPA2020529C patent/LTC2291080I2/lt unknown
- 2020-10-01 HU HUS2000038C patent/HUS2000038I1/hu unknown
- 2020-10-02 CY CY2020033C patent/CY2020033I2/el unknown

Also Published As

Publication number	Publication date
PL2913326T3 (pl)	2020-11-16
EP2291080A4 (en)	2013-09-11
PT2291080E (pt)	2015-10-30
EP3782991A1 (en)	2021-02-24
FI2291080T5 (fi)	2023-11-06
WO2009151529A1 (en)	2009-12-17
WO2009151529A9 (en)	2010-04-08
NO2020034I1 (no)	2020-09-29
CY1123338T1 (el)	2020-11-25
EA021672B1 (ru)	2015-08-31
US20120329840A1 (en)	2012-12-27
US8796318B2 (en)	2014-08-05
CY2020033I2 (el)	2021-01-27
FI2291080T3 (nl)	2015-10-15
HUE025984T2 (hu)	2016-05-30
HUS2000038I1 (hu)	2020-10-28
US20100010001A1 (en)	2010-01-14
JP2016041736A (ja)	2016-03-31
ES2549761T3 (es)	2015-11-02
SI2291080T1 (sl)	2015-11-30
NL301065I1 (nl)	2020-09-30
EA201001785A1 (ru)	2011-10-31
PT2913326T (pt)	2020-08-24
EP2291080A1 (en)	2011-03-09
AU2009258242A1 (en)	2009-12-17
US9382217B2 (en)	2016-07-05
US8530503B2 (en)	2013-09-10
EP2291080B1 (en)	2015-08-19
NZ589617A (en)	2012-06-29
AU2009258242B2 (en)	2015-07-16
LTPA2020529I1 (lt)	2020-10-26
JP5837417B2 (ja)	2015-12-24
US20180009770A1 (en)	2018-01-11
JP2011523412A (ja)	2011-08-11
AU2015213309A1 (en)	2015-09-03
US20120329838A1 (en)	2012-12-27
PL2291080T3 (pl)	2015-12-31
MY172105A (en)	2019-11-14
DK2291080T3 (en)	2015-12-07
CY2020033I1 (el)	2020-11-25
US10544136B2 (en)	2020-01-28
FIC20200037I1 (fi)	2020-09-24
US8481573B2 (en)	2013-07-09
ES2813368T3 (es)	2021-03-23
LTC2291080I2 (lt)	2021-09-10
HRP20150982T1 (hr)	2015-10-23
US8466183B2 (en)	2013-06-18
EP2913326B1 (en)	2020-07-15
MY156381A (en)	2016-02-15
EP2913326A1 (en)	2015-09-02
US20120329839A1 (en)	2012-12-27
US20170050941A1 (en)	2017-02-23
US9975863B2 (en)	2018-05-22
US20150057307A1 (en)	2015-02-26
AU2015213309B2 (en)	2016-10-13
US20190084947A1 (en)	2019-03-21

Publication	Publication Date	Title
NL301065I2 (nl)	2020-10-28	Ozanimod of een farmaceutisch aanvaardbaar zout daarvan, in het bijzonder ozanimodhydrochloride
NL301230I2 (nl)	2023-07-26	Mitapivat, dan wel een farmaceutisch aanvaardbaar zout daarvan, in het bijzonder mitapivatsulfaat
NL301305I2 (nl)	2024-12-30	Vibegron of een farmaceutisch aanvaardbaar zout daarvan
NL301256I2 (nl)	2024-01-11	cedazuridine, of een farmaceutisch aanvaardbaar zout daarvan
NL301166I2 (nl)	2022-07-06	Avacopan of een farmaceutisch aanvaardbaar zout daarvan
NL301071I2 (nl)	2020-12-01	alpelisib of een farmaceutisch aanvaardbaar zout ervan
NL301299I2 (nl)	2024-12-11	Capivasertib, eventueel in de vorm van een farmaceutisch aanvaardbaar zout
NO2020039I1 (no)	2020-11-18	Ozanimod eller et farmasøytisk akseptabelt salt derav, særlig ozanimodhydroklorid
NL301209I1 (nl)	2022-12-21	capmatinib of een farmaceutisch aanvaardbaar zout daarvan
NO2020038I1 (no)	2020-11-18	Ozanimod, or a pharmaceutically acceptable salt thereof, including the hydrochloride salt
NL301197I2 (nl)	2022-11-04	daridorexant of een farmaceutisch aanvaardbaar zout daarvan, in het bijzonder daridorexanthydrochloride
NL301057I2 (nl)	2020-09-10	Glasdegib, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout, met inbegrip van het maleaatzout
NL301067I2 (nl)	2020-10-28	Cefiderocol, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout of solvaat
NL301038I1 (nl)	2020-04-29	Netarsudil, of een zout of solvaaat daarvan, in het bijzonder netarsudilmesylaat
NL300886I2 (nl)	2017-10-24	baricitinib, of een farmaceutisch aanvaardbaar zout daarvan
NL301047I2 (nl)	2023-08-01	fosnetupitant, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout, in het bijzonder fosnetupitantchloridehydrochloride
NL301003I2 (nl)	2019-10-29	Sotagliflozin of een farmaceutisch aanvaardbaar zout daarvan
NL301291I2 (nl)	2024-10-30	sparsentan of een farmaceutisch aanvaardbaar zout daarvan
NL301250I2 (nl)	2023-11-23	piflufolastat (18F) of een farmaceutisch aanvaardbaar zout daarvan
NL300993I2 (nl)	2019-07-11	Apalutamide of een farmaceutisch aanvaardbaar zout daarvan
NL301234I2 (nl)	2023-07-26	maralixibat of een farmaceutisch aanvaardbaar zout daarvan, in het bijzonder maralixibatchloride
NL301284I2 (nl)	2024-09-04	Etrasimod, of een farmaceutisch aanvaardbaar zout daarvan, zoals etrasimod arginine
NL301021I1 (nl)	2019-12-18	talazoparib, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout.
NL301033I2 (nl)	2020-04-15	Larotrectinib, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout, in het bijzonder larotrectinibsulfaat, met inbegrip van larotrectinibsulfaat monohydraat
NL300909I2 (nl)	2017-12-19	Ribociclib, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout